Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 408-413

  Mix, T Christian H ^a   Brenner, Robert M ^a   Cooper, Mark E ^b   De Zeeuw, Dick ^c   Ivanovich, Peter ^d   Levey, Andrew S ^e   McGill, Janet B ^f   McMurray, John J V ^g   Parfrey, Patrick S ^h   Parving, Hans Henrik ⁱ   Pereira, Brian J G ^e   Remuzzi, Giuseppe ^j   Singh, Ajay K ^k   Solomon, Scott D ^k   Stehman Breen, Catherine ^a   Toto, Robert D ^l   Pfeffer, Marc A ^k  

^a AMGEN INC   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d NORTHWESTERN UNIVERSITY   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WESTERN INFIRMARY   (United Kingdom)

^h MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

ⁱ STENO DIABETES CENTER   (Denmark)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DRUG CARRIER; ERYTHROPOIETIN; ESTROGEN; GESTAGEN; HEMOGLOBIN; IRON; LOSARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALBUMIN BLOOD LEVEL; ANEMIA; BLOOD TRANSFUSION; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; GLOMERULUS FILTRATION; HEALTH CARE UTILIZATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMATOCRIT; HEMODIALYSIS; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LENGTH OF STAY; MEDICARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844369963     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.09.047     Document Type: Article

References (59)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am. J. Kidney Dis. 39 2002 S1 S266
2. J. Coresh, B.C. Astor, and T. Greene Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am. J. Kidney Dis. 41 2003 1 12
3. E.J. Lewis, L.G. Hunsicker, and R.P. Bain The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N. Engl. J. Med. 329 1993 1456 1462
4. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N. Engl. J. Med. 345 2001 851 860
5. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N. Engl. J. Med. 345 2001 861 869
6. T.H. Jafar, C.H. Schmid, and M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann. Intern. Med. 135 2001 73 87
7. P. Ruggenenti, A. Perna, and G. Gherardi Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
8. S. Klahr, A.S. Levey, and G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N. Engl. J. Med. 330 1994 877 884
9. G. Eknoyan, G.J. Beck, and A.K. Cheung Effect of dialysis dose and membrane flux in maintenance hemodialysis N. Engl. J. Med. 347 2002 2010 2019
10. D. Keith, G. Nichols, and C. Gullion Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization Arch. Intern. Med. 164 2004 659 663
11. A.I. Adler, R.J. Stevens, and S.E. Manley Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int. 63 2003 225 232
12. A.J. Collins The hemoglobin link to adverse outcomes Adv. Stud. Med. 3 2003 S14 S17
13. B.F. Culleton, M.G. Larson, and P.W. Wilson Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int. 56 1999 2214 2219
14. G. Manjunath, H. Tighiouart, and H. Ibrahim Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J. Am. Coll. Cardiol. 41 2003 47 55
15. N.B. Shulman, C.E. Ford, and W.D. Hall Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 1989 I80 I93
16. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [erratum appears in Lancet 2000;356:860] Lancet 355 2000 253 259
17. P. Gaede, P. Vedel, and H.H. Parving Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 1999 617 622
18. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N. Engl. J. Med. 348 2003 383 393
19. J.L. Abramson, C.T. Jurkovitz, and V. Vaccarino Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study Kidney Int. 64 2003 610 615
20. A. Levin, C.R. Thompson, and J. Ethier Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am. J. Kidney Dis. 34 1999 125 134
21. A. Al-Ahmad, W.M. Rand, and G. Manjunath Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction J. Am. Coll. Cardiol. 38 2001 955 962
22. W.M. McClellan, W.D. Flanders, and R.D. Langston Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study J. Am. Soc. Nephrol. 13 2002 1928 1936
23. J.J. McMurray, C.C. Lang, and K. Swedberg Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity Programme (CHARM) [abstract] 2004 American College of Cardiology Bethesda (MD)
24. W.F. Keane, B.M. Brenner, and D. de Zeeuw The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study Kidney Int. 63 2003 1499 1507
25. D.S. Silverberg, D. Wexler, and M. Blum The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol. Dial. Transplant. 18 2003 141 146
26. United States Renal Data System: USRDS 2002 annual data report 2002 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda (MD)
27. S.M. Haffner, S. Lehto, and T. Ronnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 1998 229 234
28. L.A. Moye, M.A. Pfeffer, and C.C. Wun Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study [discussion 26-30] Eur. Heart J. 15 Suppl. B 1994 2 8
29. R.N. Foley, P.S. Parfrey, and J.D. Harnett The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am. J. Kidney Dis. 28 1996 53 61
30. J.F. Mann What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol. Dial. Transplant. 14 Suppl. 2 1999 29 36
31. S. Li, and A.J. Collins Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients Kidney Int. 65 2004 626 633
32. N. Anavekar, J.J.V. McMurray, and E.J. Velazquez Influence of renal function on one year cardiovascular outcomes in the VALIANT trial [abstract] Circulation 108 Suppl. 4 2004 2221
33. A. Mohanram, J. Zhang, and S. Shahinfar Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy Kidney Int. 66 2004 1131 1138
34. K. Rossing, P.K. Christensen, and P. Hovind Progression of nephropathy in type 2 diabetic patients Kidney Int. 66 2004 1 10
35. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000 Am. J. Kidney Dis. 37 Suppl. 1 2001 S182 S238
36. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Working Party for the European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Nephrol. Dial. Transplant. 14 Suppl. 5 1999 1 50
37. F. Locatelli, R.L. Pisoni, and C. Combe Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol. Dial. Transplant. 19 2004 121 132
38. R. London, A. Solis, and G.A. Goldberg Health care resource utilization and the impact of anemia management in patients with chronic kidney disease Am. J. Kidney Dis. 40 2002 539 548
39. G.T. Obrador, T. Roberts, and W.L. St Peter Trends in anemia at initiation of dialysis in the United States Kidney Int. 60 2001 1875 1884
40. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart disease N. Engl. J. Med. 349 2003 523 534
41. Z.P. Sadowski, J.H. Alexander, and B. Skrabucha Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction Am. Heart J. 137 1999 792 798
42. R.J. Levine, J.C. Hauth, and L.B. Curet Trial of calcium to prevent preeclampsia N. Engl. J. Med. 337 1997 69 76
43. B.M. Massie, M.R. Berk, and S.C. Brozena Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor trial (FACET) Circulation 88 1993 492 501
44. M. Packer, K.A. Narahara, and U. Elkayam Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal investigators of the REFLECT study J. Am. Coll. Cardiol. 22 1993 65 72
45. M. Packer, J. Rouleau, and K. Swedberg Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract] Circulation 88 1993 I 301
46. D.J. van Veldhuisen, and P.A. Poole-Wilson The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure Int. J. Cardiol. 80 2001 19 27
47. A.M. Feldman, M.R. Bristow, and W.W. Parmley Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group N. Engl. J. Med. 329 1993 149 155
48. A.J. Cowley, and A.M. Skene Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators Br. Heart J. 72 1994 226 230
49. K.S. Kleinman, S.U. Schweitzer, and S.T. Perdue The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial Am. J. Kidney Dis. 14 1989 486 495
50. V.S. Lim, R.L. DeGowin, and D. Zavala Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial Ann. Intern. Med. 110 1989 108 114
51. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US recombinant human erythropoietin predialysis study group [erratum appears in Am J Kidney Dis 1991;18:420] Am. J. Kidney Dis. 18 1991 50 59
52. G.F.M. Strippoli, C. Manno, and F.P. Schena Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease [Cochrane Review] The Cochrane library 2004 John Wiley & Sons Chichester (UK)
53. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N. Engl. J. Med. 339 1998 584 590
54. B. Leyland-Jones, B. Investigators, and G. Study Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol. 4 2003 459 460
55. M. Henke, R. Laszig, and C. Rube Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
56. P.C. Hebert, E. Yetisir, and C. Martin Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit. Care Med. 29 2001 227 234
57. P.C. Hebert, G. Wells, and M.A. Blajchman A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group N. Engl. J. Med. 340 1999 409 417
58. G.F. Strippoli, J.C. Craig, and F.P. Schena The number, quality, and coverage of randomized controlled trials in nephrology J. Am. Soc. Nephrol. 15 2004 411 419
59. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Nephrol. Dial. Transplant. 19 Suppl. 2 2004 ii1 ii47